The study, published in European Psychiatry, has made a series of recommendations that the authors hope will deliver a better quality of care to those in need, as well as opening up the system to ensure that more people can access help.
Major Depressive Disorder (MDD) affects over 300m people worldwide at any time and is considered to have the greatest burden of disability of all illnesses due to its high prevalence, the disabling impact of depressive episodes, and low treatment response. Half of those who experience MDD will either have chronic or repetitive episodes of depression over their lifetime.
The study sourced data from papers with a focus on the treatment of depression in six European countries, including the UK, and conducted an analysis of the care pathways available to people. Despite about 30m people experiencing depression in Europe, the available data highlighted five key areas where the treatment of depression is falling down:
- Rate of detection
- Time to diagnosis and treatment
- Rates of treatment
- Frequency of follow ups after treatment
- Access to specialist services
The researchers found that approximately half of people with depression have not been diagnosed, while the average time to diagnosis can range from 1 to 8 years, depending on the study. The studies examined also showed that many patients are not undergoing treatment at any one time, with especially low rates of psychological interventions like Cognitive Behavioural Therapy (CBT).
In the UK specifically, researchers found evidence of an 8 year average wait between a person showing initial symptoms and them first contacting a health professional, while studies reporting on rates of untreated depression can be as high as 77%. Some studies suggest that rates of pharmacological treatment appear at approximately twice the rate of psychological.
Dr Rebecca Strawbridge, a post-doctoral research associate at King’s IoPPN and the study’s first author said, “It is important that, in establishing where care is failing people with depression, we also look to provide ways that those failings can be improved upon. Working collaboratively with an international group of experts, we have put forward a range of recommendations that we hope will bring current practices more into line with best practices.
“These include longer appointments with a GP, to ensure that people can be properly diagnosed, increasing treatment provision so that the ‘right’ treatment is available to each patient, greater levels of continuity of care following treatment to establish how patients have responded.”
Finally, the researchers recommend providing improved access to specialist interventions so that those with the most severe forms of the illness are not left stuck with ineffective treatments.
The researchers suggest that there are significant implications to not seeking to close the treatment gaps. Illness that goes either undetected or untreated leaves individuals at risk of worsening health. This is also a problem for those with severe needs that are unable to access more specialist services, as primary care practitioners are not equipped to treat those with more resistant forms of MDD.
This study was possible thanks to funding from the European Brain Council.
Care pathways for people with major depressive disorder: a European Brain Council Value of Treatment study (DOI10.1192/j.eurpsy.2022.28) (Rebecca Strawbridge, Paul McCrone, Andrea Ulrichsen, Roland Zahn, Jonas Eberhard, Danuta Wasserman, Paolo Brambilla, Giandomenico Schiena, Ulrich Hegerl, Judit Balazs, Jose Caldas de Almeida, Ana Antunes, Spyridon Baltzis, Vladmir Carli, Vinciane Quoidbach, Patrice Boyer, Allan H Young) was published in European Psychiatry.
For more information, please contact Patrick O’Brien (Senior Media Officer).